Evaluation of adipose tissue distribution in obese fa/fa Zucker rats by in vivo MR imaging: Effects of peroxisome proliferator-activated receptor agonists

R. Fissoune, N. Pellet, L. Chaabane, F. Contard, D. Guerrier, A. Briguet

Research output: Contribution to journalArticle

Abstract

High-resolution MRI of obese (fa/fa) Zucker rats was investigated to characterize and assess in vivo adipose tissue distribution. Thirty animals were gavaged with a placebo, a PPARγ activator (pioglitazone), or a dual PPARαγ activator (LM 4156). At day 15, T1-weighted images were acquired in vivo using a 2TMRI system with a high in-plane spatial resolution (254 μm). Fat volumes of selected territories were measured by image segmentation, and the retroperitoneal fat was weighed post-mortem. Body-weight gain was significant with pioglitazone (101.8 ± 5.9 g, P <0.01 vs. placebo). The good quality of MR images allowed the delimitation and quantification of different fat territories. In response to pioglitazone, the retroperitoneal fat was more important compared to placebo (+23%, p <0.01) while subcutaneous fat was not different. No significant effects were observed with LM 4156. In vivo measurements of fat volumes were strongly correlated with ex vivo tissue weights (r = 0.91). High-resolution MRI provides an in vivo measurement of adipose tissue distribution in obese Zucker rats. Specific fat depots of regions that were particularly involved in drug response were determined in vivo. Fat remodeling was observed with pioglitazone but not with a dual PPARαγ activator (LM 4156).

Original languageEnglish
Pages (from-to)229-235
Number of pages7
JournalMagnetic Resonance Materials in Physics, Biology, and Medicine
Volume17
Issue number3-6
DOIs
Publication statusPublished - Dec 2004

Fingerprint

pioglitazone
Zucker Rats
Peroxisome Proliferator-Activated Receptors
Tissue Distribution
Adipose Tissue
Fats
Intra-Abdominal Fat
Placebos
Subcutaneous Fat
Weight Gain
Body Weight
Weights and Measures
Pharmaceutical Preparations

Keywords

  • Adipose tissues
  • Diabetes
  • Fat remodeling
  • Magnetic resonance imaging (MRI)
  • Peroxisome proliferator-activated receptor (PPAR)

ASJC Scopus subject areas

  • Biophysics
  • Genetics

Cite this

Evaluation of adipose tissue distribution in obese fa/fa Zucker rats by in vivo MR imaging : Effects of peroxisome proliferator-activated receptor agonists. / Fissoune, R.; Pellet, N.; Chaabane, L.; Contard, F.; Guerrier, D.; Briguet, A.

In: Magnetic Resonance Materials in Physics, Biology, and Medicine, Vol. 17, No. 3-6, 12.2004, p. 229-235.

Research output: Contribution to journalArticle

@article{12e7389dcbe8435e9a6c910a5bb53113,
title = "Evaluation of adipose tissue distribution in obese fa/fa Zucker rats by in vivo MR imaging: Effects of peroxisome proliferator-activated receptor agonists",
abstract = "High-resolution MRI of obese (fa/fa) Zucker rats was investigated to characterize and assess in vivo adipose tissue distribution. Thirty animals were gavaged with a placebo, a PPARγ activator (pioglitazone), or a dual PPARαγ activator (LM 4156). At day 15, T1-weighted images were acquired in vivo using a 2TMRI system with a high in-plane spatial resolution (254 μm). Fat volumes of selected territories were measured by image segmentation, and the retroperitoneal fat was weighed post-mortem. Body-weight gain was significant with pioglitazone (101.8 ± 5.9 g, P <0.01 vs. placebo). The good quality of MR images allowed the delimitation and quantification of different fat territories. In response to pioglitazone, the retroperitoneal fat was more important compared to placebo (+23{\%}, p <0.01) while subcutaneous fat was not different. No significant effects were observed with LM 4156. In vivo measurements of fat volumes were strongly correlated with ex vivo tissue weights (r = 0.91). High-resolution MRI provides an in vivo measurement of adipose tissue distribution in obese Zucker rats. Specific fat depots of regions that were particularly involved in drug response were determined in vivo. Fat remodeling was observed with pioglitazone but not with a dual PPARαγ activator (LM 4156).",
keywords = "Adipose tissues, Diabetes, Fat remodeling, Magnetic resonance imaging (MRI), Peroxisome proliferator-activated receptor (PPAR)",
author = "R. Fissoune and N. Pellet and L. Chaabane and F. Contard and D. Guerrier and A. Briguet",
year = "2004",
month = "12",
doi = "10.1007/s10334-004-0088-y",
language = "English",
volume = "17",
pages = "229--235",
journal = "Magnetic Resonance Materials in Physics, Biology, and Medicine",
issn = "1352-8661",
publisher = "Springer Verlag",
number = "3-6",

}

TY - JOUR

T1 - Evaluation of adipose tissue distribution in obese fa/fa Zucker rats by in vivo MR imaging

T2 - Effects of peroxisome proliferator-activated receptor agonists

AU - Fissoune, R.

AU - Pellet, N.

AU - Chaabane, L.

AU - Contard, F.

AU - Guerrier, D.

AU - Briguet, A.

PY - 2004/12

Y1 - 2004/12

N2 - High-resolution MRI of obese (fa/fa) Zucker rats was investigated to characterize and assess in vivo adipose tissue distribution. Thirty animals were gavaged with a placebo, a PPARγ activator (pioglitazone), or a dual PPARαγ activator (LM 4156). At day 15, T1-weighted images were acquired in vivo using a 2TMRI system with a high in-plane spatial resolution (254 μm). Fat volumes of selected territories were measured by image segmentation, and the retroperitoneal fat was weighed post-mortem. Body-weight gain was significant with pioglitazone (101.8 ± 5.9 g, P <0.01 vs. placebo). The good quality of MR images allowed the delimitation and quantification of different fat territories. In response to pioglitazone, the retroperitoneal fat was more important compared to placebo (+23%, p <0.01) while subcutaneous fat was not different. No significant effects were observed with LM 4156. In vivo measurements of fat volumes were strongly correlated with ex vivo tissue weights (r = 0.91). High-resolution MRI provides an in vivo measurement of adipose tissue distribution in obese Zucker rats. Specific fat depots of regions that were particularly involved in drug response were determined in vivo. Fat remodeling was observed with pioglitazone but not with a dual PPARαγ activator (LM 4156).

AB - High-resolution MRI of obese (fa/fa) Zucker rats was investigated to characterize and assess in vivo adipose tissue distribution. Thirty animals were gavaged with a placebo, a PPARγ activator (pioglitazone), or a dual PPARαγ activator (LM 4156). At day 15, T1-weighted images were acquired in vivo using a 2TMRI system with a high in-plane spatial resolution (254 μm). Fat volumes of selected territories were measured by image segmentation, and the retroperitoneal fat was weighed post-mortem. Body-weight gain was significant with pioglitazone (101.8 ± 5.9 g, P <0.01 vs. placebo). The good quality of MR images allowed the delimitation and quantification of different fat territories. In response to pioglitazone, the retroperitoneal fat was more important compared to placebo (+23%, p <0.01) while subcutaneous fat was not different. No significant effects were observed with LM 4156. In vivo measurements of fat volumes were strongly correlated with ex vivo tissue weights (r = 0.91). High-resolution MRI provides an in vivo measurement of adipose tissue distribution in obese Zucker rats. Specific fat depots of regions that were particularly involved in drug response were determined in vivo. Fat remodeling was observed with pioglitazone but not with a dual PPARαγ activator (LM 4156).

KW - Adipose tissues

KW - Diabetes

KW - Fat remodeling

KW - Magnetic resonance imaging (MRI)

KW - Peroxisome proliferator-activated receptor (PPAR)

UR - http://www.scopus.com/inward/record.url?scp=14944368997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14944368997&partnerID=8YFLogxK

U2 - 10.1007/s10334-004-0088-y

DO - 10.1007/s10334-004-0088-y

M3 - Article

C2 - 15624103

AN - SCOPUS:14944368997

VL - 17

SP - 229

EP - 235

JO - Magnetic Resonance Materials in Physics, Biology, and Medicine

JF - Magnetic Resonance Materials in Physics, Biology, and Medicine

SN - 1352-8661

IS - 3-6

ER -